Lyophilisation is growing in pharma, but technical challenges persist
Lyophilisation solves several challenges in pharmaceutical supply chains while introducing new ones to fill-finish processes. We caught up with Datwyler’s…
Featured s
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval…
All Articles
Lyophilisation is growing in pharma, but technical challenges persist
Lyophilisation solves several challenges in pharmaceutical supply chains while introducing new ones to fill-finish processes. We caught up with Datwyler’s…
Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III
Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval…
Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Under the agreement, Daiichi Sankyo handles development and supply, while Innovent Biologics leads commercialisation in China.
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
ENERGI-F703DFU is currently in Phase III clinical development in both Taiwan and the US.
Tarsus joins Stargardt race to market with $800m Alkeus takeover
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market…
Context drops bispecific T-cell engager on cost-cutting initiative
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
The approval means mFlusiva becomes the first mRNA-based vaccine to be authorised on the US market for flu prevention.
Evotec and Odyssey collaborate on AI-enabled R&D
The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead
GlobalData analysts previously flagged Orzeyful’s approval as a key Q3 catalyst for the pharma industry due to the drug’s ‘transformative’…